JAK2 and myelofibrosis: However, the survival rate of myelofibrosis patients treated with INCB018424 is not different from patients treated with standard therapy [18, 19] and it is still ambiguous if the Jak2V617F allele burden is effectively improved upon Jak2 inhibitor treatment.